9. **George MP**, Kannass M, Huang L, *et al.* Respiratory symptoms and airway obstruction in HIV-infected subjects in the HAART era. *PLoS One* 2009;**4**:e6328.
10. **Gingo MR**, George MP, Kessinger CJ, *et al.* Pulmonary function abnormalities in HIV-infected patients during the current antiretroviral therapy era. *Am J Respir Crit Care Med* 2010;**182**:790–6.
11. **Cui Q**, Carruthers S, McIvor A, *et al.* Effect of smoking on lung function, respiratory symptoms and respiratory diseases amongst HIV-positive subjects: a cross-sectional study. *AIDS Res Ther* 2010;**7**:6.
12. **Vlahov D**, Anthony JC, Munoz A, *et al.* The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. *NIDA Res Monogr* 1991;**109**:75–100.
13. **Drummond MB**, Kirk GD, Ricketts EP, *et al.* Cross sectional analysis of respiratory symptoms in an injection drug user cohort: the impact of obstructive lung disease and HIV. *BMC Pulm Med* 2010;**10**:27.
14. **Miller MR**, Hankinson J, Brusasco V, *et al.* Standardisation of spirometry. *Eur Respir J* 2005;**26**:319–38.
15. **Hankinson JL**, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. *Am J Respir Crit Care Med* 1999;**159**:179–87.
16. **Pellegrino R**, Viegi G, Brusasco V, *et al.* Interpretative strategies for lung function tests. *Eur Respir J* 2005;**26**:948–68.
17. **Gomez FP**, Rodriguez-Roisin R. Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for chronic obstructive pulmonary disease. *Curr Opin Pulm Med* 2002;**8**:81–6.
18. **Orendi JM**, Bloem AC, Borleffs JC, *et al.* Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. *J Infect Dis* 1998;**178**:1279–87.
19. **Froebel KS**, Raab GM, D'Alessandro C, *et al.* A single measurement of CD38CD8 cells in HIV+, long-term surviving injecting drug users distinguishes those who will progress to AIDS from those who will remain stable. *Clin Exp Immunol* 2000;**122**:72–8.
20. **Saetta M**, Di Stefano A, Turato G, *et al.* CD8+ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 1998;**157**:822–6.
21. **Twigg HL**, Soliman DM, Day RB, *et al.* Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immunodeficiency virus infection. *Am J Respir Crit Care Med* 1999;**159**:1439–44.
22. **Yearsley MM**, Diaz PT, Kneoll D, *et al.* Correlation of HIV-1 detection and histology in AIDS-associated emphysema. *Diagn Mol Pathol* 2005;**14**:48–52.
23. **Matsumoto T**, Miike T, Nelson RP, *et al.* Elevated serum levels of IL-8 in patients with HIV infection. *Clin Exp Immunol* 1993;**93**:149–51.
24. **Lahdevirta J**, Maury CP, Teppo AM, *et al.* Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. *Am J Med* 1988;**85**:289–91.
25. **Barnes PJ**. The cytokine network in asthma and chronic obstructive pulmonary disease. *J Clin Invest* 2008;**118**:3546–56.
26. **Karadag F**, Karul AB, Cildag O, *et al.* Biomarkers of systemic inflammation in stable and exacerbation phases of COPD. *Lung* 2008;**186**:403–9.
27. **Motz GT**, Eppert BL, Wesselkamper SC, *et al.* Chronic cigarette smoke exposure generates pathogenic T cells capable of driving COPD-like disease in Rag2-/- mice. *Am J Respir Crit Care Med* 2010;**181**:1223–33.
28. **Shirai T**, Suda T, Inui N, *et al.* Correlation between peripheral blood T-cell profiles and clinical and inflammatory parameters in stable COPD. *Allergol Int* 2010;**59**:75–82.
29. **Harik-Khan RI**, Fleg JL, Wise RA. Body mass index and the risk of COPD. *Chest* 2002;**121**:370–6.
30. **Celli BR**, Cote CG, Marin JM, *et al.* The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *N Engl J Med* 2004;**350**:1005–12.
31. **Kanazawa H**, Hirata K, Yoshikawa J. Accelerated decline of lung function in COPD patients with chronic hepatitis C virus infection: a preliminary study based on small numbers of patients. *Chest* 2003;**123**:596–9.
32. **Kanazawa H**, Yoshikawa J. Accelerated decline in lung function and impaired reversibility with salbutamol in asthmatic patients with chronic hepatitis C virus infection: a 6-year follow-up study. *Am J Med* 2004;**116**:749–52.
33. **Silva DR**, Stiff J, Cheinquer H, *et al.* Prevalence of hepatitis C virus infection in patients with COPD. *Epidemiol Infect* 2010;**138**:167–73.

Journal club

Outpatient management of pulmonary embolism

This multi-national, randomised trial compared outpatient versus inpatient care in patients with acute pulmonary embolism with a low risk of death (severity index category of I or II). Both groups were treated with enoxaparin (≥ 5 days) and oral anticoagulation (≥ 90 days).

One of the 171 outpatients and none of the 168 inpatients had recurrence of venous thromboembolism within 90 days, meeting the non-inferiority criteria ($<4\%$ between group difference). With respect to secondary outcomes, two outpatients and no inpatients had major bleeding (intramuscular haematomas) within 14 days. There was one death in each group, neither related to the trial. There was no statistically significant difference in use of medical resources between groups. However, the outpatients had non-significantly more home visits for enoxaparin injections.

The limitations of this trial include the fact that it was an open-label trial, although steps were taken to reduce bias. In addition, the enoxaparin regime used was 1 mg/kg twice a day as opposed to the usual 1.5 mg/kg every 24 h. This could have affected the venous thromboembolism recurrence rate.

This well-designed study suggests that outpatient treatment of acute pulmonary embolism can be safe, effective and efficient compared with inpatient treatment when the patient group is very carefully selected. However, the occurrence of potentially avoidable major bleeding and recurrence of venous thromboembolism even in this select group are causes for concern. Further studies are required before this treatment can be routinely recommended as standard practice.

► **Aujesky D**, Roy PM, Verschuren F, *et al.* Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. *Lancet* 2011;**378**:41–8.

Sheena Barnett

Correspondence to Sheena Barnett, ST6 Respiratory Medicine, Royal London Hospital, Barts and the London NHS Trust, Whitechapel Road, Whitechapel, London E1 1BB, UK; snovelend@hotmail.com

Provenance and peer review Not commissioned; internally peer reviewed.

Published Online First 28 September 2011

Thorax 2012;**67**:314. doi:10.1136/thoraxjnl-2011-201090